23CAS955: A randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa-high recurrent platinum-sensitive epithelial ovarian, fallopi

Principal Investigator

Study Number

STUDY02001955

Summary

This study is for patients who have platinum-sensitive ovarian cancer that has come back after a first -round of treatment, who are currently on or recently have completed a second round of treatment with triplet therapy (meaning, a combination treatment with a platinum agent and bevacizumab (BEV)plus one of the following: paclitaxel or gemcitabine or pegylated lysosomal doxorubicin (PLD)), whose tumor has tested positive for high levels of folate receptor-alpha (FR ), and whose cancer has not worsened following the recent triplet therapy. The main purpose of this study is to learn more about the new drug called mirvetuximab soravtansine (MIRV) and determine if it is effective at preventing or delaying the return of platinum-sensitive ovarian cancer when administered after a triplet therapy regimen in combination with BEV.

Phase

Available at the following location(s)

Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms